Industry Research Reports
Home > Reports > Pharma & Healthcare > Global Biosimilar Drug Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Biosimilar Drug Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Industry: Pharma & Healthcare
Published Date: 2025-03-19
Pages: 78 Pages
Report ld: 4678150
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
The global Biosimilar Drug market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product"s patent expires.
In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.
East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.
In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.
The global Biosimilar Drug market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
MARKET SEGMENTATION
By Company
- CP Guojian Pharma
- Biotech Pharma
- Celgen Pharma
- Henlius
- Amgen
- Eli Lilly
- Sandoz
- Changchun High Tech
- Innovent
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Injection
- Tablets
- Other Types
Segment by Application
- Ankylosing Spondylitis
- Tumor
- Rheumatoid Arthrtis
- Cardiovascular
- Other Application
CHAPTER OUTLINE
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Biosimilar Drug market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Tablets in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Tumor in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Injection dominance in Europe vs. Tablets demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Biosimilar Drug Product Scope
1.2 Biosimilar Drug by Type
1.2.1 Global Biosimilar Drug Sales by Type (2020 & 2024 & 2031)
1.2.2 Injection
1.2.3 Tablets
1.2.4 Other Types
1.3 Biosimilar Drug by Application
1.3.1 Global Biosimilar Drug Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Ankylosing Spondylitis
1.3.3 Tumor
1.3.4 Rheumatoid Arthrtis
1.3.5 Cardiovascular
1.3.6 Other Application
1.4 Global Biosimilar Drug Market Estimates and Forecasts (2020-2031)
1.4.1 Global Biosimilar Drug Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Biosimilar Drug Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Biosimilar Drug Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Biosimilar Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Biosimilar Drug Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Biosimilar Drug Sales Market Share by Region (2020-2025)
2.2.2 Global Biosimilar Drug Revenue Market Share by Region (2020-2025)
2.3 Global Biosimilar Drug Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Biosimilar Drug Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Biosimilar Drug Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Biosimilar Drug Market Size and Prospective (2020-2031)
2.4.2 Europe Biosimilar Drug Market Size and Prospective (2020-2031)
2.4.3 China Biosimilar Drug Market Size and Prospective (2020-2031)
2.4.4 Japan Biosimilar Drug Market Size and Prospective (2020-2031)
2.4.5 Singapore Biosimilar Drug Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Biosimilar Drug Historic Market Review by Type (2020-2025)
3.1.1 Global Biosimilar Drug Sales by Type (2020-2025)
3.1.2 Global Biosimilar Drug Revenue by Type (2020-2025)
3.1.3 Global Biosimilar Drug Price by Type (2020-2025)
3.2 Global Biosimilar Drug Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Biosimilar Drug Sales Forecast by Type (2026-2031)
3.2.2 Global Biosimilar Drug Revenue Forecast by Type (2026-2031)
3.2.3 Global Biosimilar Drug Price Forecast by Type (2026-2031)
3.3 Different Types Biosimilar Drug Representative Players
4 Global Market Size by Application
4.1 Global Biosimilar Drug Historic Market Review by Application (2020-2025)
4.1.1 Global Biosimilar Drug Sales by Application (2020-2025)
4.1.2 Global Biosimilar Drug Revenue by Application (2020-2025)
4.1.3 Global Biosimilar Drug Price by Application (2020-2025)
4.2 Global Biosimilar Drug Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Biosimilar Drug Sales Forecast by Application (2026-2031)
4.2.2 Global Biosimilar Drug Revenue Forecast by Application (2026-2031)
4.2.3 Global Biosimilar Drug Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Biosimilar Drug Application
5 Competition Landscape by Players
5.1 Global Biosimilar Drug Sales by Players (2020-2025)
5.2 Global Top Biosimilar Drug Players by Revenue (2020-2025)
5.3 Global Biosimilar Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Drug as of 2024)
5.4 Global Biosimilar Drug Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Biosimilar Drug, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Biosimilar Drug, Product Type & Application
5.7 Global Key Manufacturers of Biosimilar Drug, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Biosimilar Drug Sales by Company
6.1.1.1 North America Biosimilar Drug Sales by Company (2020-2025)
6.1.1.2 North America Biosimilar Drug Revenue by Company (2020-2025)
6.1.2 North America Biosimilar Drug Sales Breakdown by Type (2020-2025)
6.1.3 North America Biosimilar Drug Sales Breakdown by Application (2020-2025)
6.1.4 North America Biosimilar Drug Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Biosimilar Drug Sales by Company
6.2.1.1 Europe Biosimilar Drug Sales by Company (2020-2025)
6.2.1.2 Europe Biosimilar Drug Revenue by Company (2020-2025)
6.2.2 Europe Biosimilar Drug Sales Breakdown by Type (2020-2025)
6.2.3 Europe Biosimilar Drug Sales Breakdown by Application (2020-2025)
6.2.4 Europe Biosimilar Drug Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Biosimilar Drug Sales by Company
6.3.1.1 China Biosimilar Drug Sales by Company (2020-2025)
6.3.1.2 China Biosimilar Drug Revenue by Company (2020-2025)
6.3.2 China Biosimilar Drug Sales Breakdown by Type (2020-2025)
6.3.3 China Biosimilar Drug Sales Breakdown by Application (2020-2025)
6.3.4 China Biosimilar Drug Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Biosimilar Drug Sales by Company
6.4.1.1 Japan Biosimilar Drug Sales by Company (2020-2025)
6.4.1.2 Japan Biosimilar Drug Revenue by Company (2020-2025)
6.4.2 Japan Biosimilar Drug Sales Breakdown by Type (2020-2025)
6.4.3 Japan Biosimilar Drug Sales Breakdown by Application (2020-2025)
6.4.4 Japan Biosimilar Drug Major Customer
6.4.5 Japan Market Trend and Opportunities
6.5 Singapore Market: Players, Segments, Downstream and Major Customers
6.5.1 Singapore Biosimilar Drug Sales by Company
6.5.1.1 Singapore Biosimilar Drug Sales by Company (2020-2025)
6.5.1.2 Singapore Biosimilar Drug Revenue by Company (2020-2025)
6.5.2 Singapore Biosimilar Drug Sales Breakdown by Type (2020-2025)
6.5.3 Singapore Biosimilar Drug Sales Breakdown by Application (2020-2025)
6.5.4 Singapore Biosimilar Drug Major Customer
6.5.5 Singapore Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 CP Guojian Pharma
7.1.1 CP Guojian Pharma Company Information
7.1.2 CP Guojian Pharma Business Overview
7.1.3 CP Guojian Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.1.4 CP Guojian Pharma Biosimilar Drug Products Offered
7.1.5 CP Guojian Pharma Recent Development
7.2 Biotech Pharma
7.2.1 Biotech Pharma Company Information
7.2.2 Biotech Pharma Business Overview
7.2.3 Biotech Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Biotech Pharma Biosimilar Drug Products Offered
7.2.5 Biotech Pharma Recent Development
7.3 Celgen Pharma
7.3.1 Celgen Pharma Company Information
7.3.2 Celgen Pharma Business Overview
7.3.3 Celgen Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Celgen Pharma Biosimilar Drug Products Offered
7.3.5 Celgen Pharma Recent Development
7.4 Henlius
7.4.1 Henlius Company Information
7.4.2 Henlius Business Overview
7.4.3 Henlius Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Henlius Biosimilar Drug Products Offered
7.4.5 Henlius Recent Development
7.5 Amgen
7.5.1 Amgen Company Information
7.5.2 Amgen Business Overview
7.5.3 Amgen Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Amgen Biosimilar Drug Products Offered
7.5.5 Amgen Recent Development
7.6 Eli Lilly
7.6.1 Eli Lilly Company Information
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Eli Lilly Biosimilar Drug Products Offered
7.6.5 Eli Lilly Recent Development
7.7 Sandoz
7.7.1 Sandoz Company Information
7.7.2 Sandoz Business Overview
7.7.3 Sandoz Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Sandoz Biosimilar Drug Products Offered
7.7.5 Sandoz Recent Development
7.8 Changchun High Tech
7.8.1 Changchun High Tech Company Information
7.8.2 Changchun High Tech Business Overview
7.8.3 Changchun High Tech Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Changchun High Tech Biosimilar Drug Products Offered
7.8.5 Changchun High Tech Recent Development
7.9 Innovent
7.9.1 Innovent Company Information
7.9.2 Innovent Business Overview
7.9.3 Innovent Biosimilar Drug Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Innovent Biosimilar Drug Products Offered
7.9.5 Innovent Recent Development
8 Biosimilar Drug Manufacturing Cost Analysis
8.1 Biosimilar Drug Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Biosimilar Drug
8.4 Biosimilar Drug Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Biosimilar Drug Distributors List
9.3 Biosimilar Drug Customers
10 Biosimilar Drug Market Dynamics
10.1 Biosimilar Drug Industry Trends
10.2 Biosimilar Drug Market Drivers
10.3 Biosimilar Drug Market Challenges
10.4 Biosimilar Drug Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Biosimilar Drug Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Biosimilar Drug Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Biosimilar Drug Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Biosimilar Drug Sales (K Dose) by Region (2020-2025)
Table 5. Global Biosimilar Drug Sales Market Share by Region (2020-2025)
Table 6. Global Biosimilar Drug Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Biosimilar Drug Revenue Share by Region (2020-2025)
Table 8. Global Biosimilar Drug Sales (K Dose) Forecast by Region (2026-2031)
Table 9. Global Biosimilar Drug Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Biosimilar Drug Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Biosimilar Drug Revenue Share Forecast by Region (2026-2031)
Table 12. Global Biosimilar Drug Sales by Type (K Dose) & (2020-2025)
Table 13. Global Biosimilar Drug Sales Share by Type (2020-2025)
Table 14. Global Biosimilar Drug Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Biosimilar Drug Price by Type (USD/Dose) & (2020-2025)
Table 16. Global Biosimilar Drug Sales by Type (K Dose) & (2026-2031)
Table 17. Global Biosimilar Drug Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Biosimilar Drug Price by Type (USD/Dose) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Biosimilar Drug Sales by Application (K Dose) & (2020-2025)
Table 21. Global Biosimilar Drug Sales Share by Application (2020-2025)
Table 22. Global Biosimilar Drug Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Biosimilar Drug Price by Application (USD/Dose) & (2020-2025)
Table 24. Global Biosimilar Drug Sales by Application (K Dose) & (2026-2031)
Table 25. Global Biosimilar Drug Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Biosimilar Drug Price by Application (USD/Dose) & (2026-2031)
Table 27. New Sources of Growth in Biosimilar Drug Application
Table 28. Global Biosimilar Drug Sales by Company (K Dose) & (2020-2025)
Table 29. Global Biosimilar Drug Sales Share by Company (2020-2025)
Table 30. Global Biosimilar Drug Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Biosimilar Drug Revenue Share by Company (2020-2025)
Table 32. Global Biosimilar Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Drug as of 2024)
Table 33. Global Market Biosimilar Drug Average Price by Company (USD/Dose) & (2020-2025)
Table 34. Global Key Manufacturers of Biosimilar Drug, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Biosimilar Drug, Product Type & Application
Table 36. Global Key Manufacturers of Biosimilar Drug, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Biosimilar Drug Sales by Company (2020-2025) & (K Dose)
Table 39. North America Biosimilar Drug Sales Market Share by Company (2020-2025)
Table 40. North America Biosimilar Drug Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Biosimilar Drug Revenue Market Share by Company (2020-2025)
Table 42. North America Biosimilar Drug Sales by Type (2020-2025) & (K Dose)
Table 43. North America Biosimilar Drug Sales Market Share by Type (2020-2025)
Table 44. North America Biosimilar Drug Sales by Application (2020-2025) & (K Dose)
Table 45. North America Biosimilar Drug Sales Market Share by Application (2020-2025)
Table 46. Europe Biosimilar Drug Sales by Company (2020-2025) & (K Dose)
Table 47. Europe Biosimilar Drug Sales Market Share by Company (2020-2025)
Table 48. Europe Biosimilar Drug Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Biosimilar Drug Revenue Market Share by Company (2020-2025)
Table 50. Europe Biosimilar Drug Sales by Type (2020-2025) & (K Dose)
Table 51. Europe Biosimilar Drug Sales Market Share by Type (2020-2025)
Table 52. Europe Biosimilar Drug Sales by Application (2020-2025) & (K Dose)
Table 53. Europe Biosimilar Drug Sales Market Share by Application (2020-2025)
Table 54. China Biosimilar Drug Sales by Company (2020-2025) & (K Dose)
Table 55. China Biosimilar Drug Sales Market Share by Company (2020-2025)
Table 56. China Biosimilar Drug Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Biosimilar Drug Revenue Market Share by Company (2020-2025)
Table 58. China Biosimilar Drug Sales by Type (2020-2025) & (K Dose)
Table 59. China Biosimilar Drug Sales Market Share by Type (2020-2025)
Table 60. China Biosimilar Drug Sales by Application (2020-2025) & (K Dose)
Table 61. China Biosimilar Drug Sales Market Share by Application (2020-2025)
Table 62. Japan Biosimilar Drug Sales by Company (2020-2025) & (K Dose)
Table 63. Japan Biosimilar Drug Sales Market Share by Company (2020-2025)
Table 64. Japan Biosimilar Drug Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Biosimilar Drug Revenue Market Share by Company (2020-2025)
Table 66. Japan Biosimilar Drug Sales by Type (2020-2025) & (K Dose)
Table 67. Japan Biosimilar Drug Sales Market Share by Type (2020-2025)
Table 68. Japan Biosimilar Drug Sales by Application (2020-2025) & (K Dose)
Table 69. Japan Biosimilar Drug Sales Market Share by Application (2020-2025)
Table 70. Singapore Biosimilar Drug Sales by Company (2020-2025) & (K Dose)
Table 71. Singapore Biosimilar Drug Sales Market Share by Company (2020-2025)
Table 72. Singapore Biosimilar Drug Revenue by Company (2020-2025) & (US$ Million)
Table 73. Singapore Biosimilar Drug Revenue Market Share by Company (2020-2025)
Table 74. Singapore Biosimilar Drug Sales by Type (2020-2025) & (K Dose)
Table 75. Singapore Biosimilar Drug Sales Market Share by Type (2020-2025)
Table 76. Singapore Biosimilar Drug Sales by Application (2020-2025) & (K Dose)
Table 77. Singapore Biosimilar Drug Sales Market Share by Application (2020-2025)
Table 78. CP Guojian Pharma Company Information
Table 79. CP Guojian Pharma Description and Business Overview
Table 80. CP Guojian Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. CP Guojian Pharma Biosimilar Drug Product
Table 82. CP Guojian Pharma Recent Development
Table 83. Biotech Pharma Company Information
Table 84. Biotech Pharma Description and Business Overview
Table 85. Biotech Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. Biotech Pharma Biosimilar Drug Product
Table 87. Biotech Pharma Recent Development
Table 88. Celgen Pharma Company Information
Table 89. Celgen Pharma Description and Business Overview
Table 90. Celgen Pharma Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Celgen Pharma Biosimilar Drug Product
Table 92. Celgen Pharma Recent Development
Table 93. Henlius Company Information
Table 94. Henlius Description and Business Overview
Table 95. Henlius Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. Henlius Biosimilar Drug Product
Table 97. Henlius Recent Development
Table 98. Amgen Company Information
Table 99. Amgen Description and Business Overview
Table 100. Amgen Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Amgen Biosimilar Drug Product
Table 102. Amgen Recent Development
Table 103. Eli Lilly Company Information
Table 104. Eli Lilly Description and Business Overview
Table 105. Eli Lilly Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. Eli Lilly Biosimilar Drug Product
Table 107. Eli Lilly Recent Development
Table 108. Sandoz Company Information
Table 109. Sandoz Description and Business Overview
Table 110. Sandoz Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. Sandoz Biosimilar Drug Product
Table 112. Sandoz Recent Development
Table 113. Changchun High Tech Company Information
Table 114. Changchun High Tech Description and Business Overview
Table 115. Changchun High Tech Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. Changchun High Tech Biosimilar Drug Product
Table 117. Changchun High Tech Recent Development
Table 118. Innovent Company Information
Table 119. Innovent Description and Business Overview
Table 120. Innovent Biosimilar Drug Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 121. Innovent Biosimilar Drug Product
Table 122. Innovent Recent Development
Table 123. Production Base and Market Concentration Rate of Raw Material
Table 124. Key Suppliers of Raw Materials
Table 125. Biosimilar Drug Distributors List
Table 126. Biosimilar Drug Customers List
Table 127. Biosimilar Drug Market Trends
Table 128. Biosimilar Drug Market Drivers
Table 129. Biosimilar Drug Market Challenges
Table 130. Biosimilar Drug Market Restraints
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Biosimilar Drug Product Picture
Figure 2. Global Biosimilar Drug Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Biosimilar Drug Sales Market Share by Type in 2024 & 2031
Figure 4. Injection Product Picture
Figure 5. Tablets Product Picture
Figure 6. Other Types Product Picture
Figure 7. Global Biosimilar Drug Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 8. Global Biosimilar Drug Sales Market Share by Application in 2024 & 2031
Figure 9. Ankylosing Spondylitis Examples
Figure 10. Tumor Examples
Figure 11. Rheumatoid Arthrtis Examples
Figure 12. Cardiovascular Examples
Figure 13. Other Application Examples
Figure 14. Global Biosimilar Drug Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Biosimilar Drug Sales Growth Rate (2020-2031) & (US$ Million)
Figure 16. Global Biosimilar Drug Sales (K Dose) Growth Rate (2020-2031)
Figure 17. Global Biosimilar Drug Price Trends Growth Rate (2020-2031) & (USD/Dose)
Figure 18. Biosimilar Drug Report Years Considered
Figure 19. Global Market Biosimilar Drug Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 20. Global Biosimilar Drug Revenue Market Share by Region: 2020 VS 2024
Figure 21. North America Biosimilar Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 22. North America Biosimilar Drug Sales (K Dose) Growth Rate (2020-2031)
Figure 23. Europe Biosimilar Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 24. Europe Biosimilar Drug Sales (K Dose) Growth Rate (2020-2031)
Figure 25. China Biosimilar Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 26. China Biosimilar Drug Sales (K Dose) Growth Rate (2020-2031)
Figure 27. Japan Biosimilar Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 28. Japan Biosimilar Drug Sales (K Dose) Growth Rate (2020-2031)
Figure 29. Singapore Biosimilar Drug Revenue (US$ Million) Growth Rate (2020-2031)
Figure 30. Singapore Biosimilar Drug Sales (K Dose) Growth Rate (2020-2031)
Figure 31. Global Biosimilar Drug Revenue Share by Type (2020-2025)
Figure 32. Global Biosimilar Drug Sales Share by Type (2026-2031)
Figure 33. Global Biosimilar Drug Revenue Share by Type (2026-2031)
Figure 34. Global Biosimilar Drug Revenue Share by Application (2020-2025)
Figure 35. Global Biosimilar Drug Revenue Growth Rate by Application in 2020 & 2024
Figure 36. Global Biosimilar Drug Sales Share by Application (2026-2031)
Figure 37. Global Biosimilar Drug Revenue Share by Application (2026-2031)
Figure 38. Global Biosimilar Drug Sales Share by Company (2024)
Figure 39. Global Biosimilar Drug Revenue Share by Company (2024)
Figure 40. Global 5 Largest Biosimilar Drug Players Market Share by Revenue in Biosimilar Drug: 2020 & 2024
Figure 41. Biosimilar Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 42. Manufacturing Cost Structure of Biosimilar Drug
Figure 43. Manufacturing Process Analysis of Biosimilar Drug
Figure 44. Biosimilar Drug Industrial Chain
Figure 45. Channels of Distribution (Direct Vs Distribution)
Figure 46. Distributors Profiles
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Biosimilar Drug market?
The top companies in the global Biosimilar Drug market are CP Guojian Pharma、Biotech Pharma、Celgen Pharma.
Related Reports
Global Biosimilar Drug Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Biosimilar Drug market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 79
USD 4250.00
(Single User License)
Global Biosimilar Drug Market Research Report 2026
The global Biosimilar Drug market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-04
Pages: 111
USD 2900.00
(Single User License)
Biosimilar Drug- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Biosimilar Drug was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-04
Pages: 97
USD 3950.00
(Single User License)
Global Biosimilar Drug Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Biosimilar Drug market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 141
USD 4900.00
(Single User License)
Global Biosimilar Drug Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Biosimilar Drug was estimated to be worth US$ million and is forecast to reach approximately US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 132
USD 5900.00
(Single User License)
Biosimilar Drug- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Biosimilar Drug was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 104
USD 3950.00
(Single User License)
Global Biosimilar Drug Market Research Report 2025
The global market for Biosimilar Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-01-16
Pages: 84
USD 2900.00
(Single User License)
Global Biosimilar Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
Published Date: 2024-04-17
Pages: 140
USD 5600.00
(Single User License)
Global Biosimilar Drug Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
Published Date: 2024-04-16
Pages: 123
USD 5900.00
(Single User License)
Global Biosimilar Drug Market Insights, Forecast to 2030
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
Published Date: 2024-04-07
Pages: 93
USD 4900.00
(Single User License)
Global Biosimilar Drug Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Biosimilar Drug market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 79
USD 4250.00 (Single User License)Global Biosimilar Drug Market Research Report 2026
The global Biosimilar Drug market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-01-04
Pages: 111
USD 2900.00 (Single User License)Biosimilar Drug- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Biosimilar Drug was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-01-04
Pages: 97
USD 3950.00 (Single User License)Global Biosimilar Drug Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Biosimilar Drug market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 141
USD 4900.00 (Single User License)Global Biosimilar Drug Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Biosimilar Drug was estimated to be worth US$ million and is forecast to reach approximately US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 132
USD 5900.00 (Single User License)Biosimilar Drug- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Biosimilar Drug was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 104
USD 3950.00 (Single User License)Global Biosimilar Drug Market Research Report 2025
The global market for Biosimilar Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-01-16
Pages: 84
USD 2900.00 (Single User License)Global Biosimilar Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
Published: 2024-04-17
Pages: 140
USD 5600.00 (Single User License)Global Biosimilar Drug Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
Published: 2024-04-16
Pages: 123
USD 5900.00 (Single User License)Global Biosimilar Drug Market Insights, Forecast to 2030
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
Published: 2024-04-07
Pages: 93
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4250.00
USD 6375.00
USD 8500.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now